knowledge -WSS

knowledge

author：leisure time 2025-10-01 23:59:08 - browse：93251

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： AdventHealth escalates lawsuit against insurance vendor Multiplan

hotspot

WSS

Why psychiatrists like me stop taking insurance

Ending racial health disparities hinges on penalties, political will

New weight loss drugs work. But how can they best be used?

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

3 medical device trends to watch in 2024

Ahead of JPM, here's who's profiting most in health care

entertainment

knowledge

focus

Activists slam private health insurers over coverage restrictions

Feng Zhang CRISPR delivery startup lays off quarter of staff

Hepatitis C has a cure — but many Americans still lack access to it

Stanford president's case begs question: Who takes blame?

United colonoscopy coverage change 'may cost lives,' doctors say

J&J to buy cancer drug developer Ambrx Biopharma

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The biotech scorecard for Q1: 17 stock

Novavax promises a turnaround & Lilly roils the obesity market

White House finalizes ITC's import ban of latest Apple Watches

hotspot

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Goldman Sachs launches $650M fund for life science investments

I learned firsthand about improving diversity in clinical trials

7 more heat

Mass General totes up its waste in a move to tackle climate change

Ahead of JPM, here's who's profiting most in health care

hotspot

knowledge

leisure time

hotspot